OncoMatch/Clinical Trials/NCT06438627
Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
Is NCT06438627 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including TPC combined with Apatinib and Camrelizumab and GP Combined With Camrelizumab for nasopharyngeal carcinoma.
Treatment: TPC combined with Apatinib and Camrelizumab · GP Combined With Camrelizumab — This study aims to evaluate the efficacy and safety of the TPC regimen (nab-paclitaxel, cisplatin, and capecitabine) combined with apatinib and camrelizumab versus the GP regimen (gemcitabine and cisplatin) combined with camrelizumab for the treatment of high-risk regionally advanced nasopharyngeal carcinoma with a high risk of distant metastasis. The evaluation will be conducted through a prospective, controlled, open-label, multicenter phase 3 clinical trial in areas with high incidence of nasopharyngeal carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage TANYN3M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
neutrophils ≥1.5×10^9/l, platelets ≥100×10^9/l, hemoglobin ≥90 g/l
Kidney function
creatinine <1.5 times the upper limit of normal
Liver function
transaminases <2.5 times the upper limit of normal, total bilirubin <1.5 times the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify